سعر سفينجومود 0.5 مجم 28 كبسولة 2026

Fingolimod 0.5 mg oral capsules, pack of 28; Hikma Specialized Pharmaceuticals, Egypt.

• Relapsing forms of multiple sclerosis (clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease).Population: Adults and pediatric patients 10 years of age and olderDailyMed (U.S. National Library of Medicine)

• Most common (10% or more and greater than placebo): headache, liver transaminase elevation, diarrhoea, cough, influenza, sinusitis, back pain, abdominal pain and pain in extremity.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• In the last 6 months: myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalisation, or class III/IV heart failure.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• History or presence of Mobitz type II second-degree or third-degree AV block or sick sinus syndrome, unless a functioning pacemaker is present; baseline QTc of 500 msec or more; arrhythmias requiring class Ia or class III antiarrhythmics.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to fingolimod or any excipient (rash, urticaria and angioedema reported at initiation).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Bradyarrhythmia and AV block after the first dose; first-dose monitoring is required.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Increased risk of infections, including serious and opportunistic infections and progressive multifocal leukoencephalopathy (PML); do not start during active infection; monitor during treatment and for 2 months after stopping; avoid live attenuated vaccines.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Macular oedema (higher risk with diabetes or uveitis): fundus examination at baseline, at 3-4 months and with any visual change.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• QT-prolonging drugs with known risk of torsades de pointesMonitor overnight with continuous ECG in a medical facility when starting fingolimod.DailyMed (U.S. National Library of Medicine)
• Systemic ketoconazoleFingolimod and fingolimod-phosphate levels increase 1.7-fold; monitor closely.DailyMed (U.S. National Library of Medicine)
• Live attenuated vaccinesAvoid during treatment and for 2 months after stopping (risk of infection; reduced vaccine response).DailyMed (U.S. National Library of Medicine)

• Observational registry data suggest an increased prevalence of major birth defects; animal studies showed developmental toxicity. Stop 2 months before planned conception, considering the possibility of severe increase in disability after discontinuation.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; fingolimod is excreted in rat milk. Weigh the benefits of breastfeeding against the mother's clinical need and potential infant risk.International label, same formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.